Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder

African Journal of Psychiatry (South Africa)

Volumn 11, Issue 4, 2008, Pages 287-290

  Koen, Liezl ^a,b   Magni, P ^a   Niehaus, D J H ^a   le Roux, A ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b NONE   (South Africa)

Author keywords

Practice guidelines; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOLOGICAL RATING SCALE; RESIDENTIAL CARE; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOUTH AFRICA; UNSPECIFIED SIDE EFFECT;

EID: 69949084398     PISSN: 19948220     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. National Institute for Clinical Excellence. Schizophrenia - Full national clinical guideline on core interventions in primary and secondary care. ISBN 1-901242-97-8. Trowbridge, Wiltshire, UK: Royal College of Psychiatrists and the British Psychological Society; 2003.
2. Miller AL, Hal lCS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65:500-8.
3. American Psychiatric Association. American Psychiatric Association Practice Guidelines. Available from: http://www.psych.org/psych_pract/ treatg/pg/prac_guide.cfm.
4. Bauer M. A review of quantitative studies of adherence to mental health clinical practice guidelines. Harv Rev Psychiatry. 2002; 10:138-53.
5. Gilbert DA, Altshuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry. 1998;59:345-51.
6. Seedat S, Emsley RA, Stein DJ. Land of promise: challenges and opportunities for research in South Africa. Mol Psychiatry. 2004; 9:891-2.
7. Kuno E, Rothbard A. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry. 2002;159:567-72.
8. Herbeck DM, West JC, Ruditis I, Duffy FF, Fitek DJ, Bell CC, et al. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv. 2004;55:677-84.
9. Segal SP, Bola JR, Watson MA. Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv. 1996;47:282-
10. Niehaus DJ, Koen L, Laurent C, Muller J, Deleuze JF, Mallet J, et al. Positive and negative symptoms in affected sib pairs with schizophrenia: implications for genetic studies in an African Xhosa sample. Schizophr Res. 2005;79:239-49.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Fourth Edition ed. Washington, DC: American Psychiatric Association; 2000.
12. Nurnberger JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features and training. NIMH Genetics Initiative. Arch Gen Psychiatry. 1994;51:849-59.
13. Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry. 1989;7:49-58.
14. Andreasen NC, Arndt S, Miller D, Flaum M, Nopoulos P. Correlation studies of the scale for the assessment of negative symptoms and the scale for the assessment of positive symptoms: an overview and update. Psychopathology. 1995;28:7-17.
15. Covell NH, Jackson CT, Evans AC, Essak SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002;28:17-29.
16. Wheeler A. Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions. N Z Med J. 2006;119:1237.
17. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis - incidence and risk factors in the United States. N Engl J Med. 1993 July 15, 1993;329(3):162-7.
18. Lieberman JA, Safferman AZ. Clinical profile of clozapine: Adverse reactions and agranulocytosis. Psychiatr Q. 1992;63(1):51-70.
19. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines - international survey and comparison. Br J Psychiatry. 2005;187:248-55.
20. Joubert AF. Providing quality care to patients with schizophrenia. Psychiatric Clinics of North America. 2003;26(1):213-30.
21. Leape LL, Weissman JS, Schneider EC, Piana RN, Gatsonis L, Epstein AM. Adherence to practice guidelines: the role of specialty society guidelines. Am Heart J. 2003;145:19-26.
22. Rush AJ, Rago VW, Crismon ML, Toprac MG, Shon SP, Suppes T, et al. Medication treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project. J Clin Psychiatry. 1999; 60:284-91.
23. Lawson WB. Clinical issues in the pharmacotherapy of African-Americans. Psychopharmacol Bull. 1996;32:275-81.
24. Lin K, Anderson D, Poland RE. Ethnicity and psychopharmacology: bridging the gap. Psyciatr Clin North Am. 1995;18:635-47.
25. Brindis R, Sennett C. Physician adherence to clinical practice guidelines: does it really matter? Am Heart J. 2003;145:13-5.
26. Parks JJ. Implementing practice guidelines: lessons from public mental health settings. J Clin Psychiatry. 2007;68(suppl 4):45-8.